SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025. It plans to buy back shares worth 5 billion euro in 2025.

Sanofi wants to position Nexviazyme as the new standard of treatment for late-onset Pompe disease, and has claimed approval ahead of its closest rival Amicus Therapeutics, which has filed a ...

More than 85% of Altuviiio’s sales were in the United States. New drug, Nexviazyme/Nexviadzyme recorded sales of €184 million, up 42.0% year over year. While sales were strong in Europe and ...